The Efficacy impact of donor temporary deferal on the safety of blood donations in Iran during the years 2012-2014
Journal Title: Khoon - Year 2019, Vol 16, Issue 1
Abstract
The Efficacy impact of donor temporary deferal on the safety of blood donations in Iran during the years 2012-2014 Hatami H.1, Maghsudlu M.2, Balali M.R.2, Seyfi Targhi M.M.2 1School of Public Helath and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran 2Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran Abstract Background and Objectives Iranian Blood Transfusion Organization, to maintain the health of blood donors and recipients, defines the eligibility criteria for conducting blood donation process without which blood donors are deferred. Previous studies have shown the necessity of deferral criteria for blood safety. This study showed that deferral of these volunteers has improved the health of blood donors; it has been determined based on the frequency of both positive confirmatory screening test results in blood donors on their return and temporary deferral rates especially due to high risk behaviors. Materials and Methods The study was cross-sectional descriptive. Data collection was performed based on all the data of blood donation volunteers included in the NEGAREH software. The data were then analyzed by Chi-square and Excel software. Results Out of 6,877,627 volunteers during 2012-2014, 1,416,791 volunteers were deferred from blood donation. The prevalence of infectious markers in blood donors was 0.19% (10354 donations); the prevalence was 0.018% in 2,784,593 donations of donors on return (493 donors); and for 460,559 donations of deferrals it was 0.209% (975 donors). The prevalence of infectious markers for donations on return was 0.225% (211 donations) for risky behaviors and 0.205% (764 donations) for the other deferred donors. Conclusions It has been shown that the prevalence rate of the confirmed screening test results for Transfusion Transmitted Infections especially HBSAg is higher in repeat and regular donors once temporalily deferred (particularly for high risk behaviors) and returned for donation than those without the deferral record; it shows their deferral has been effective in improving blood safety. Key words: Blood Donors, Donor Selection, Iran Received: 6 Aug 2018 Accepted: 13 Jan 2018 Correspondence: Balali M.R., MD. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine. P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052165; Fax: (+9821) 82052165 E-mail: rezabalali@yahoo.com
Authors and Affiliations
H. Hatami, M. Maghsudlu, M. R. Balali, M. M. Seyfi Targhi
Evaluation of demographic characteristics and hepatitis B,C and HIV prevalence among blood donors in Jahrom
Evaluation of demographic characteristics and hepatitis B,C and HIV prevalence among blood donors in Jahrom Emamghorashi F.2 (MD ), Fathi G.H.2 (MD ), Mohtashami A.1,3(MD ) 1Iranian Blood Transfusion Organizati...
Study of the implementation status of archival records in Iranian Blood Transfusion Centers
Study of the implementation status of archival records in Iranian Blood Transfusion Centers Rafiee M.H.1, Amini Kafi-abad S.1 1Blood Transfusion Research Center, High Institute for Research and Education in Transfusi...
Oxytocin efficiency in differentiation of P19c16 stem cells into cardiomyocytes
Oxytocin efficiency in differentiation of P19c16 stem cells into cardiomyocytes Fathi F.1(PhD), Bagheban Eslami M.R.2(PhD), Ahsan B.1(MD), Alasvand M.1(MS), Rezaei M.J.1(PhD), Pirmoradi L.1(MS), Asahara T.3(MD)...
ارزيابي بتا ـ2 ميكروگلوبولين (2MG) در سرم بيماران مبتلا به منوكلونال و پلي كلونال گاماپاتي
چكيده سابقه و هدف بتا-2 ميكروگلوبولين ، پروتئيني است با وزن مولكولي 11800 دالتون كه توسط سلولهاي هستهدار ساخته ميشود. اين پروتئين اولين باردر ادرار بيماران مبتلا به نارسايي كليه تخليص شده است . افزايش سطح سرمي ب...
HOTAIR expression in newly diagnosed Acute Lymphoblastic Leukemia pateints
HOTAIR expression in newly diagnosed Acute Lymphoblastic Leukemia pateints Fallah P.1, Molaie M.2, Ehsan Heidari A.3, Soleimani M.4, Jahedi Zargar M.1, Arefian E.5, Madani T.6, Asadi M.3, Poopak B.7 1Allied-Health F...